The first phase 3 data with UCB’s key pipeline drug bimekizumab ... Patients in the study had at least 10% of their body covered with psoriasis at enrolment. The trial provides “strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback